

OFFICIAL
amt
2/6/2003**FULBRIGHT & JAWORSKI L.L.P.**A REGISTERED LIMITED LIABILITY PARTNERSHIP
666 FIFTH AVENUE, 31ST FLOOR
NEW YORK, NEW YORK 10103-3198
WWW.FULBRIGHT.COM**FACSIMILE TRANSMISSION****DATE:** February 6, 2003**MATTER NUMBER:**

10016355

RECIPIENT(S):	FAX NO.:	PHONE NO.:
Examiner A. Harris USPTO, Group 1642	703-746-4987	

FROM: Norman Hanson**USER ID:** NH01030**FLOOR:** 24**PHONE:** (212) 318-3168**FAX:** (212) 318-3400**RE:****NUMBER OF PAGES WITH COVER PAGE:** 7**Message:**

--

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
_____ AT _____ AS SOON AS POSSIBLE.

LUD-5353.5 JEL/NDH (10016355)

VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on February 6, 2003.

Fulbright & Jaworski L.L.P.

Laurie O'Leary

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant : Beatrice GAUGLER et al.
Serial No. : 09/579,543
Filed : May 26, 2000
For : ISOLATED NUCLEIC ACID MOLECULES CODING FOR
TUMOR REJECTION ANTIGEN PRECURSOR MAGE-4
AND 41 AND USES THEREOF
Art Unit : 1642
Examiner : Alana Harris

February 6, 2003

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

SUPPLEMENTAL AMENDMENT

This follows the telephone conference with the examiner which took place on February 5.
Applicants regret any confusion caused during the prosecution of this case.

Please amend this application as follows:

IN THE CLAIMS

Cancel claims 59 and 62, without prejudice.

Amend claims 39 & 41, replace them with the following:

Claim 39: An isolated nucleic acid molecule which encodes a fragment of a tumor rejection antigen precursor expressed in melanoma cells, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 13, 14 or 15 at 0.1XSSC, 0.1%SDS for 30 minutes, at 65°C.

25260311.1